Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2011-03-08
2011-03-08
Ha, Julie (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S372300, C530S300000, C530S327000, C530S328000
Reexamination Certificate
active
07901902
ABSTRACT:
Filamin-B peptides, compositions comprising such peptides, and methods of using such peptides to assess an immune response against such peptides are described. An immune response against the peptides correlates with an immune response, in particular a cellular immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
REFERENCES:
patent: 5637483 (1997-06-01), Dranoff et al.
patent: 5904920 (1999-05-01), Dranoff et al.
patent: 5985290 (1999-11-01), Jaffee et al.
patent: 6033674 (2000-03-01), Jaffee et al.
patent: 6277368 (2001-08-01), Hiserodt et al.
patent: 6350445 (2002-02-01), Jaffee et al.
patent: 6464973 (2002-10-01), Levitsky et al.
patent: 2006/0057127 (2006-03-01), Liu et al.
patent: WO 2000/072686 (2000-12-01), None
Definition of Insect Cells from http://www.biochem.northwestern.edu/holmgren/Glossary/Definitions/Def-1/insect—cells.html, p. 1. Accessed Apr. 13, 2009.
Immortalized Cells from http://www.microbiologybytes.com/video/culture.html, pp. 1-5. Accessed Apr. 13, 2009.
Rudinger J, “Characteristics of the amino acids as components of a peptide hormone sequence,” Peptide Hormones, JA Parsons Edition, University Park Press, Jun. 1976, pp. 1-7.
“Designing Custom Peptides,” from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Schinzel R, Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” FEBS, Jul. 1991, 286(1,2): 125-128.
Berendsen HJC, “A Glimpse of the Holy Grail?” Science, 1998, 282: 642-643.
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Ngo JT, Marks J, Karplus M, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495.
Bradley CM, Barrick D, “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol., 2002, 324: 373-386.
Introduction to Cancer from Merck manual, p. 1. Accessed Mar. 5, 2008.
Clinical Aspects of Cancer from Merck manual, pp. 1-4. Accessed Mar. 5, 2008.
Auerbach R, Akhtar N, Lewis RL, Shinners BL, “Angiogenesis assays: Problems and pitfalls,” Cancer and Metastasis Reviews, 2000, 19: 167-172.
Gura Trisha, “Systems for Identifying New Drugs Are Often Faulty,” Science, 1997, 278: 1041-1042.
Jain Rakesh K, “Barriers to Drug Delivery in Solid Tumors,” Scientific American, Jul. 1994, 58-65.
Abe et al., “Antitumor Effect Induced by Granulocyte/Macrophage-Colony-Stimulating Factor Gene-Modified Tumor Vaccination: Comparison of Adenovirus- and Retrovirus-Mediated Genetic Transduction,” J. Cancer Res. Clin. Oncol., 121:587-592 (1995).
Altschul et al., “Basic Local Alignment Search Tool,” J. Mol. Biol., 215:403-410 (1990).
Aoki et al., “Expression of Murine Interleukin 7 in a Murine Glioma Cell Line Results in Reduced Tumorigenicity in Vivo,” Proc. Natl. Acad. Sci. USA, 89:3850-3854 (1992).
Armstrong et al., “Cytokine Modified Tumor Vaccines,” Surg. Oncol. Clin. N. Am., 11:681-696 (2002).
Batzer et al., “Enhanced Evolutionary PCR Using Oligonucleotides with Inosine at the 3′-Terminus,” Nucleic Acids Res., 19(18):5081 (1991).
Bodey et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,” Anticancer Res., 20:2665-2676 (2000).
Boon et al., “Cancer Tumor Antigens,” Immunology, 9:681-683 (1997).
Borrello et al., “GM-CSF-Based Cellular Vaccines: A Review of the Clinical Experience,” Cytokine & Growth Factor Reviews, 13:185-193 (2002).
Cantrell et al., “Cloning, Sequence, and Expression of a Human Granulocyte/Macrophage Colony-Stimulating Factor,” Proc. Natl. Acad. Sci. USA, 82:6250-6254 (1985).
Chang et al., “Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor,” Human Gene Therapy, 11:839-850 (2000).
Darrow et al., “The Role of HLA Class I Antigens in Recognition of Melanoma Cells by Tumor-Specific Cytotoxic T Lymphocytes,” J. of Immunology, 142(9):3329-3335 (1989).
Doytchinova et al., “EpiJen: A Server for Multistep T Cell Epitope Prediction,” BMC Bioinformatics, 7:131, pp. 1-11 (2006).
Dranoff et al., “Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity,” Proc. Natl. Acad. Sci. USA, 90:3539-3543 (1993).
Fearon et al., “Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response,” Cell, 60:397-403 (1990).
Forni et al., “Helper Strategy in Tumor Immunology: Expansion of Helper Lymphocytes and utilization of Helper Lymphokines for Experimental and Clinical Immunotherapy,” Cancer and Metastasis Reviews, 7:289-309 (1988).
Gansbacher et al., “Retroviral Vector-Mediated γ-Interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity,” Cancer Research, 50:7820-7825 (1990).
Gansbacher et al., “Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity,” J. Exp. Med., 172:1217-1224 (1990).
Gasson, “Molecular Physiology of Granulocyte-Macrophage Colony-Stimulating Factor,” Blood, 77(6):1131-1145 (1991).
Golumbek et al., “Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4,” Science, 254:713-716 (1991).
Guan et al., “MHCPred 2.0: An Updated Quantitative T-Cell Epitope Prediction Server,” Appl. Bioinformatics, 5(1):55-61 (2006).
Hattotuwagama et al., “Quantitative Online Prediction of Peptide Binding to the Major Histocompatibility Complex,” J. Molecular Graphics and Modelling, 22:195-207 (2004).
Hock et al., “Interleukin 7 Induces CD4+T Cell-Dependent Tumor Rejection,” J. Exp. Med., 174:1291-1298 (1991).
Hom et al., “Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction,” J. Immunotherapy, 10:153-164 (1991).
Huang et al., “Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens,” Science, 264:961-965 (1994).
Huebner et al., “The Human Gene Encoding GM-CSF Is at 5q21-q32, the Chromosome Region Deleted in the 5q−Anomaly,” Science, 230:1282-1285 (1985).
Jaffee et al., “Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor—Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation,” J. Clinical Oncology, 19(1):145-156 (2001).
Jaffee et al., “Gene Therapy: Its Potential Applications in the Treatment of Renal-Cell Carcinoma,” Seminars in Oncology, 22(1):81-91 (1995).
Kawakami et al., “Shared Human Melanoma Antigens: Recognition by Tumor-Infiltrating Lymphocytes in HLA-A2.1-Transfected Melanomas,” J. Of Immunology, 148(2):638-643 (1992).
Kesmir et al., “Prediction of Proteasome Cleavage Motifs by Neural Networks,” Protein Engineering, 15(4):287-296 (2002).
Klein et al., “Properties of the K562 Cell Line, Derived from a Patient with Chronic Myeloid Leukemia,” Int. J. Cancer, 18:421-431 (1976).
Lee et al., “Genetic Immunotherapy of Established Tumors with Adenovirus-Murine Granulocyte-Macrophage Colony-Stimulating Factor,” Human Gene Therapy, 8:187-193 (1997).
Leedman et al., “Clo
Bae Joo-eun
Jooss Karin
BioSante Pharmaceuticals, Inc.
Ha Julie
Jones Day
LandOfFree
Methods and compositions for identifying a cellular immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for identifying a cellular immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for identifying a cellular immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731274